Ceritinib
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Ceritinib |
| DrugBank ID | DB09063 |
| Brand Names (EU) | Zykadia |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.86% |
Approved Indication (EMA)
Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | fibromatosis, gingival | 99.86% | DL |
| 2 | fibroma of lung | 99.82% | DL |
| 3 | hamartoma of lung | 99.81% | DL |
| 4 | lung hilum carcinoma | 99.80% | DL |
| 5 | lung benign neoplasm | 99.80% | DL |
| 6 | pulmonary sulcus neoplasm | 99.80% | DL |
| 7 | lung germ cell tumor | 99.80% | DL |
| 8 | inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia | 99.79% | DL |
| 9 | Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome | 99.78% | DL |
| 10 | junctional epidermolysis bullosa | 99.77% | DL |
| 11 | ovarioleukodystrophy | 99.72% | DL |
| 12 | junctional epidermolysis bullosa, non-Herlitz type | 99.71% | DL |
| 13 | lung cancer | 99.71% | DL |
| 14 | dehydratase deficiency | 99.68% | DL |
| 15 | Ewing sarcoma | 98.81% | DL |
| 16 | amyotrohpic lateral sclerosis type 22 | 94.01% | DL |
| 17 | orbit sarcoma | 93.89% | DL |
| 18 | synovial chondromatosis | 93.89% | DL |
| 19 | ganglioneuroblastoma (disease) | 93.45% | DL |
| 20 | giant cell tumor of soft tissue | 93.43% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.